Samsung to invest $10 million in US-based C2N Diagnostics

Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...

LG, Jackson Lab to jointly develop AI models for Alzheimer’s, cancers

LG AI Research, the artificial intelligence research arm of South Korea’s LG Group, and the Jackson Laboratory (JAX), a US non-profit biomedic...

ISU Abxis gets patent for Alzheimer drug candidate in Taiwan

South Korea's ISU Abxis Co. announced on Friday that its Alzheimer's treatment candidate ISU203 has received a substance patent registration decisio...

NKMax to perform first tests on dementia cell therapy in US

NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...

NGeneBio applies for US patent of early diagnosis tech of dementia

South Korean medical diagnostic company NGeneBio Co. announced on Thursday that it has completed the US patent application for its technology relate...

Novartis $391 mn deal powers Samsung Biologics backlogs to record high

Samsung Biologics Co., the world’s top contract manufacturing organization by capacity, inked a $391 million contract from Novartis, nearly fi...

Bredis Healthcare, Tilda win June D.Day, Korea’s oldest startup pitch race

An early-stage startup by young entrepreneurs who developed a digital diagnostic tool for brain disease and an AI-powered business optimization prog...

Neurophet strives to be first mover in fight against Alzheimer’s

Neurophet Inc., a South Korean startup developing artificial intelligence-powered medical solutions for brain diseases, is striving to make a breakt...

Neurophet acquires Singaporean certification for Alzheimer's diagnosis

South Korea's medical imaging device maker Neurophet said on Tuesday that its SCALE PET has obtained a medical device certification from the Health ...